Quick Takeaways:
- PetVivo entered a Termination and Settlement Agreement with VetStem, effective July 24, 2026, ending their Exclusive License and Supply Agreement for PrecisePRP. The deal resolves outstanding invoices, royalties, milestones and other claims, while establishing an orderly transition of inventory and commercial activities.
- Under the settlement, PetVivo’s sole remaining financial obligation is $75,000 through two scheduled cash payments. An additional payment may apply if transferred inventory falls below agreed minimum quantities. Remaining PrecisePRP inventory will be returned to VetStem, while VetStem’s warrant for 250,000 PetVivo shares remains valid.
- The agreement includes mutual releases covering substantially all claims under the prior deal, subject to customary continuing obligations. PetVivo said the settlement allows it to focus resources on proprietary technologies, including SPRYNG with OsteoCushion Technology, and its broader growth strategy.
Why It Matters?
By terminating the PrecisePRP arrangement with VetStem, PetVivo removes outstanding invoices, royalties and milestone overhangs from a non-core product line, which should simplify the story for investors and management while freeing attention and capital for SPRYNG with OsteoCushion Technology and broader equine/companion-animal commercialization.
Source: Globenewswire
